Device Trial Radar · NCT05371795
Comparison on Radiotherapy Permanent Skin Marking With Lancets and an Electric Marking Device
Last checked: Nov 20, 2026Latest source record: Jun 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
100
Actual
Start
Oct 18, 2021
Primary completion
Mar 11, 2022
Study completion Sep 2022
Sponsor
- Lead sponsor
- Instituto Portugues de Oncologia, Francisco Gentil, PortoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 12, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Comparison on radiotherapy skin set-up markings with lancets versus Comfort Marker 2.0®
Conditions
- Radiotherapy
- Tattooing
Interventions
Comfort Marker 2.0Device
The set-up markings are created during the simulation session, after the CT simulation is acquired. For the experimental group, patients' markings are tattooed using an electric marking device developed for set-up marking, the Comfort Marker 2.0® (CM), designed by CIVCO medical solutions, using the 0.2mm deep application depth and the brand-included black pigment. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.
LancetsDevice
The set-up markings are created during the simulation session, after the CT simulation is acquired. For the control group, patients' markings are tattooed using a 28-gauge disposable lancet and india ink. After cleaning the excess ink, if the tattooing was considered unsuccessful, the process was repeated. Markings arrangement followed our departmental protocol. No limit on the maximum number of cutaneous reference points is specified.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patients' comfortTime frame: Day 1
- EffectivenessTime frame: up to 7 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Instituto Português de Oncologia do Porto Francisco Genti
Porto, Portugal
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.